Opiant Pharmaceuticals, Inc. (OPNT): Price and Financial Metrics
GET POWR RATINGS... FREE!
OPNT POWR Grades
- Value is the dimension where OPNT ranks best; there it ranks ahead of 90.46% of US stocks.
- The strongest trend for OPNT is in Momentum, which has been heading down over the past 28 weeks.
- OPNT's current lowest rank is in the Momentum metric (where it is better than 2.41% of US stocks).
OPNT Stock Summary
- OPNT has a market capitalization of $60,065,339 -- more than approximately just 10.07% of US stocks.
- With a year-over-year growth in debt of 2,898.4%, Opiant Pharmaceuticals Inc's debt growth rate surpasses 99.4% of about US stocks.
- Opiant Pharmaceuticals Inc's shareholder yield -- a measure of how much capital is returned to stockholders via dividends and buybacks -- is -32.07%, greater than the shareholder yield of just 8.26% of stocks in our set.
- Stocks that are quantitatively similar to OPNT, based on their financial statements, market capitalization, and price volatility, are BBI, AXGN, FRD, SHSP, and COCP.
- Visit OPNT's SEC page to see the company's official filings. To visit the company's web site, go to www.opiant.com.
OPNT Stock Price Chart Interactive Chart >
OPNT Price/Volume Stats
|Current price||$13.88||52-week high||$14.98|
|Prev. close||$14.19||52-week low||$6.79|
|Day high||$14.10||Avg. volume||31,094|
|50-day MA||$12.49||Dividend yield||N/A|
|200-day MA||$10.26||Market Cap||60.11M|
Opiant Pharmaceuticals, Inc. (OPNT) Company Bio
Opiant Pharmaceuticals, Inc., a specialty pharmaceutical company, develops opioid antagonist treatments for addictions and related disorders. The company offers NARCAN nasal spray, a treatment to reverse opioid overdoses. It is also involved in developing treatments for binge eating disorder and cocaine use disorder, as well as Bulimia Nervosa, an eating disorder; and heroin vaccine. The company was formerly known as Lightlake Therapeutics Inc. and changed its name to Opiant Pharmaceuticals, Inc. in January 2016. Opiant Pharmaceuticals, Inc. was founded in 2005 and is based in Santa Monica, California. Opiant Pharmaceuticals, Inc. operates as a subsidiary of Pelikin Group.
OPNT Latest News Stream
|Loading, please wait...|
OPNT Latest Social Stream
View Full OPNT Social Stream
Latest OPNT News From Around the Web
Below are the latest news stories about Opiant Pharmaceuticals Inc that investors may wish to consider to help them evaluate OPNT as an investment opportunity.
Legendary fund manager Li Lu (who Charlie Munger backed) once said, 'The biggest investment risk is not the volatility...
SANTA MONICA, Calif., May 24, 2021 (GLOBE NEWSWIRE) -- Opiant Pharmaceuticals, Inc. (“Opiant”) (NASDAQ: OPNT), a specialty pharmaceutical company developing medicines for addictions and drug overdose, announced today that its Chief Executive Officer, Dr. Roger Crystal, will present at the Jefferies Virtual Healthcare Conference, from 3:30-3:55pm ET on Thursday, June 3, 2021. Opiant will also host 1x1 investor meetings during the conference. A live webcast of the presentation will be available under ‘Events & Presentations’ in the Investors section of the Opiant website: www.opiant.com. A replay of the webcast will be available for 30 days following the conclusion of the live presentation broadcast. About Opiant Pharmaceuticals, Inc.Opiant Pharmaceuticals, Inc., the company that develope...
By David Bautz, PhD NASDAQ:OPNT READ THE FULL OPNT RESEARCH REPORT Business Update OPNT003 PD and PK Studies Ongoing In February 2021, Opiant Pharmaceuticals, Inc. (NASDAQ:OPNT) announced that the confirmatory pharmacokinetic (PK) study for OPNT003, an intranasal (IN) formulation of nalmefene, is underway. The open label, randomized, crossover study will enroll 68 healthy volunteers and will
Opiant Pharmaceuticals Announces First Subjects Dosed in Study Comparing OPNT003, Nasal Nalmefene, With Nasal Naloxone
Pharmacodynamic study will compare OPNT003, nasal nalmefene, with nasal naloxone in reversing the respiratory depression produced by the synthetic opioid, remifentanilTop-line data expected in the fourth quarter This trial starts at a time when deaths resulting from opioid overdose are at record highs SANTA MONICA, Calif., April 05, 2021 (GLOBE NEWSWIRE) -- Opiant Pharmaceuticals, Inc. (“Opiant”) (NASDAQ: OPNT), a specialty pharmaceutical company developing medicines to treat addictions and drug overdose, today announced that the first subjects were dosed in a head-to-head clinical study comparing the effectiveness of its investigational opioid antagonist OPNT003, nasal nalmefene, with nasal naloxone. The single-center, randomized, open-label study in heathy volunteers will evaluate the...
Opiant Pharmaceuticals Announces Final Tranche of NIDA Grant Award for its Investigational Treatment for Opioid Overdose
SANTA MONICA, Calif., March 31, 2021 (GLOBE NEWSWIRE) -- Opiant Pharmaceuticals, Inc. (“Opiant”) (NASDAQ: OPNT), a specialty pharmaceutical company developing medicines to treat addictions and drug overdose, has been awarded the third and final tranche of $1.8 million from the total grant of approximately $7.4 million from the National Institute on Drug Abuse (“NIDA”), part of the National Institutes of Health (“NIH”), to support the development of OPNT003, nasal nalmefene, for the treatment of opioid overdose. The grant was awarded under award number 5U01DA046093-03. With the substantial increase in drug overdose deaths across the United States, primarily driven by rapid increases in overdose deaths involving synthetic opioids, including illicitly manufactured fentanyl1, NIH leadership...
OPNT Price Returns
Continue Researching OPNTHere are a few links from around the web to help you further your research on Opiant Pharmaceuticals Inc's stock as an investment opportunity:
Opiant Pharmaceuticals Inc (OPNT) Stock Price | Nasdaq
Opiant Pharmaceuticals Inc (OPNT) Stock Quote, History and News - Yahoo Finance
Opiant Pharmaceuticals Inc (OPNT) Stock Price and Basic Information | MarketWatch